2658-6533Research Results in Biomedicine2658-653310.18413/2313-8955-2017-3-4-30-381278Archive categoriesPHYTODRUGS, ANALYSIS OF RUSSIAN FEDERATION PHARMACEUTICAL MARKETPHYTODRUGS, ANALYSIS OF RUSSIAN FEDERATION PHARMACEUTICAL MARKETBoykoNikolay N.BoykoNikolay N.boykoniknik@gmail.comBondarevAlexander V.BondarevAlexander V.ZhilyakovaElena T.ZhilyakovaElena T.ezhilyakova@bsu.edu.ruPisarevDmitri I.PisarevDmitri I.juniper05@mail.ruNovikovOleg O.NovikovOleg O.ole9222@yandex.ru20173400

Up to know plant raw material and drugs based on it (tinctures, extracts, highly purified extracts, individual substance drugs) play an important role in pharmacotherapy of many chronic and continuous sluggish human diseases. As it was presented in our study phytodrugs amount up to 25 % from the total number of registered drugs in Russia and depending to their content distributed in following order: “Combination drugs” (8,54 %), “Extraction drugs (extracts, tinctures, oils)” (5,27 %), “Individual substance drugs” (5,00 %), “Medicinal plant raw material” (3,95 %), “Highly purified extracts” (1,91 %). The most frequently drug dosage forms have been found: between solid dosage forms were tablets (7,36 %), capsules (1,68 %), powders/granules (0,91 %), between liquid dosage forms were solutions (3,65 %), tinctures (2.3 %), extracts (0,32%), and between plant raw materials were herbs (1,02 %), leaves (0,82 %), collections (0,62 %), flowers (0,45 %), fruits (0,32 %) and roots/rhizomes (0,30 %). It was found that most of phytodrugs belong to following pharmacotherapy groups: A Alimentary tract and metabolism (5,62 %), N Nervous system (5,06 %), R Respiratory system (4,24 %), C Cardiovascular system (2,96 %), and L Antineoplastic and immunomodulating agents (2,76 %). It was noted that diseases of these systems belong to widespread in human, and drugs have stable demand. It was found that approximately 2,4 % of phytodrugs (from all number of registered drugs in Russia) in form of “Individual substance drugs” belong to group of life–saving drugs that is used for treatment of oncology diseases.

Up to know plant raw material and drugs based on it (tinctures, extracts, highly purified extracts, individual substance drugs) play an important role in pharmacotherapy of many chronic and continuous sluggish human diseases. As it was presented in our study phytodrugs amount up to 25 % from the total number of registered drugs in Russia and depending to their content distributed in following order: “Combination drugs” (8,54 %), “Extraction drugs (extracts, tinctures, oils)” (5,27 %), “Individual substance drugs” (5,00 %), “Medicinal plant raw material” (3,95 %), “Highly purified extracts” (1,91 %). The most frequently drug dosage forms have been found: between solid dosage forms were tablets (7,36 %), capsules (1,68 %), powders/granules (0,91 %), between liquid dosage forms were solutions (3,65 %), tinctures (2.3 %), extracts (0,32%), and between plant raw materials were herbs (1,02 %), leaves (0,82 %), collections (0,62 %), flowers (0,45 %), fruits (0,32 %) and roots/rhizomes (0,30 %). It was found that most of phytodrugs belong to following pharmacotherapy groups: A Alimentary tract and metabolism (5,62 %), N Nervous system (5,06 %), R Respiratory system (4,24 %), C Cardiovascular system (2,96 %), and L Antineoplastic and immunomodulating agents (2,76 %). It was noted that diseases of these systems belong to widespread in human, and drugs have stable demand. It was found that approximately 2,4 % of phytodrugs (from all number of registered drugs in Russia) in form of “Individual substance drugs” belong to group of life–saving drugs that is used for treatment of oncology diseases.

intima media thickness of the common carotid arterycoronary atherosclerosiscoronary artery diseasetype 2 diabetes mellitusintima media thickness of the common carotid arterycoronary atherosclerosiscoronary artery diseasetype 2 diabetes mellitusСписок литературыAlekseeva, E. (2002), “Phytodrugs in current rational pharmacotherapy”, Ros.apteki, 2, 23-27. Russian.Afanas'eva, T. G. (2003), “Marketing studies of phytodrugs in local market level”, Abstract of Ph.D. dissertation, KGMU, Kursk, Russia. Russian.Afanas'eva, T. G. (2006), “Marketing analysis of assortment of phytodrugs Russian market”, Vestnik VGU, Serija: Himija. Biologija. Farmacija, 2, 206-208. Russian.Belousova, O. V., Belousov, E. A., Ivashhenkova, A. O. (2016), “Biologically active supplements as a perspective direction of development of the pharmaceutical market”, Nauchnyj rezul'tat. Medicina i farmacija, 4(4), 89-94. Russian.Bulaev, V. M., Shih, E. V., Sychev, D. A. (2013), “Bezopasnost' i jeffektivnost' lekarstvennyh rastenij” [Safety and effectiveness of medicinal plants], 2nd ed., Prakticheskaja medicina, Moscow, Russia. Russian.Gosudarstvennyj reestr lekarstvennyh sredstv (2017), [Online], available at: https://grls.rosminzdrav.ru/Default.aspx (Accessed 10 November 2017). Russian.The official site of Registr lekarstvennyh sredstv Rossii, (2017), [Online], available at: https://www.rlsnet.ru (Accessed 10 November 2017). Russian.Rusakova, O.A., Ral'cheko, I.V., Gerbert, I.Ja., Verdieva, S.I. (2015), “The study for the pharmacy range of herbal medicinal products”, Farmacija i farmakologija, 6(13), 54-59. Russian.Tehnologija lekarstv promyshlennogo proizvodstva [Technology of drugs] (2014), V. 2, Ch.1, Translated from Ukrainian by Chueshov, V.I., Gladuh, E.V., Sajko, I.V. et al. Novaja Kniga, Vinnica, Ukraina. Russian.Shirokova, I. (2013), “Phytodrugs market tendency, problems, forecasts”, Remedium, 4(194), 26-33. Russian.Ernst, E., Pittler, M.H. (2002), “Risks associated with herbal medicinal products”, Wien Med Wochenschr, 152(7-8), 183-9.Posadzki, P., Watson L.K., Ernst E. (2013), “Adverse effects of herbal medicines: an overview of systematic reviews”, Clin Med (Lond), Feb, 13(1), 7-12.